- Home
- NRSN vs ADVM Comparison
NRSN vs ADVM Comparison
Compare NRSN & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- ADVM
- Stock Information
- Founded
- NRSN 2017
- ADVM 2006
- Country
- NRSN Israel
- ADVM United States
- Employees
- NRSN N/A
- ADVM N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRSN Health Care
- ADVM Health Care
- Exchange
- NRSN Nasdaq
- ADVM Nasdaq
- Market Cap
- NRSN 45.3M
- ADVM 47.4M
- IPO Year
- NRSN 2021
- ADVM 2014
- Fundamental
- Price
- NRSN $1.91
- ADVM $2.39
- Analyst Decision
- NRSN Buy
- ADVM Strong Buy
- Analyst Count
- NRSN 2
- ADVM 5
- Target Price
- NRSN $14.00
- ADVM $23.80
- AVG Volume (30 Days)
- NRSN 427.0K
- ADVM 338.5K
- Earning Date
- NRSN 07-15-2025
- ADVM 08-11-2025
- Dividend Yield
- NRSN N/A
- ADVM N/A
- EPS Growth
- NRSN N/A
- ADVM N/A
- EPS
- NRSN N/A
- ADVM N/A
- Revenue
- NRSN N/A
- ADVM $1,000,000.00
- Revenue This Year
- NRSN N/A
- ADVM N/A
- Revenue Next Year
- NRSN N/A
- ADVM $18.82
- P/E Ratio
- NRSN N/A
- ADVM N/A
- Revenue Growth
- NRSN N/A
- ADVM N/A
- 52 Week Low
- NRSN $0.51
- ADVM $1.78
- 52 Week High
- NRSN $2.60
- ADVM $10.14
- Technical
- Relative Strength Index (RSI)
- NRSN 48.94
- ADVM 44.19
- Support Level
- NRSN $1.81
- ADVM $2.11
- Resistance Level
- NRSN $1.96
- ADVM $2.60
- Average True Range (ATR)
- NRSN 0.20
- ADVM 0.22
- MACD
- NRSN -0.08
- ADVM -0.00
- Stochastic Oscillator
- NRSN 19.10
- ADVM 33.33
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.